Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2024-02-20 Earnings Release
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Earnings presentation for Quarter 3 - Financial year 2023-24
Earnings Release Classification · 95% confidence The document is titled 'Earnings Presentation for Quarter 3 – Financial Year 2023-2024' and includes detailed financial data such as quarterly and nine-month standalone and consolidated financial performance, revenue, EBITDA margins, profit/loss, EPS, and operational highlights. It is an extensive presentation with about 15,000 characters, containing actual financial results and analysis for Q3 and 9M FY24. The document is not merely an announcement or a brief summary but a detailed presentation of earnings results. Therefore, it fits the category of an Earnings Release (ER) document, which is the initial announcement of quarterly financial results with key highlights and detailed financial data. Q3 2024
2024-02-20 English
Newspaper Publication regarding dispatch of Postal Ballot Notice
Regulatory Filings
2024-02-17 English
Notice of postal ballot
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Postal Ballot Notice issued under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It is addressed to the stock exchange and shareholders, informing them about the dispatch of the Postal Ballot Notice for approval of a special resolution regarding the appointment of an Independent Director. The document includes explanatory statements, voting instructions, and statutory references but does not contain financial statements or results. It is a notice for shareholder voting rather than a report or announcement of voting results. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-02-16 English
Sale of premises
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to the stock exchange (BSE Limited) regarding the execution of a sale deed for office premises. It references prior shareholder approval and provides details of the transaction, including parties involved, terms, and confirmation that it is not a related party transaction. The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, which mandates disclosure of material events. The content is a notification of a corporate transaction (sale of asset) rather than a financial report, earnings release, or management discussion. It is not a full report but an announcement of a significant event affecting the company. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-14 English
Newspaper publication of unaudited financial results for the quarter and nine months ended December 31, 2023.
Regulatory Filings
2024-02-13 English
Announcement for (1) Appointment of Additional (Independent) Director, (2) Postal Ballot, (3) Appointment of Compliance Officer and (4) Appointment of Secretarial Auditor
Board/Management Information Classification · 100% confidence The document is a formal announcement from a company to the stock exchange regarding the outcome of a Board Meeting held on February 12, 2024. It details the appointment of an additional independent director, the approval of a postal ballot notice for the director's appointment, the appointment of a new compliance officer, and the appointment of a secretarial auditor. The document references compliance with SEBI regulations and includes annexures with detailed disclosures about the appointments. There are no financial statements, earnings data, or detailed management discussion and analysis. The content focuses on board and management changes and regulatory compliance disclosures. Therefore, this document fits the category of Board/Management Information (MANG).
2024-02-12 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.